This small-cap Pharma Stock, engaged in manufacturing active pharmaceutical ingredients (APIs) and conducting research and development to deliver high-quality, innovative healthcare solutions globally, jumped 6 percent after the promoter increased their stake by 4.16 percent, worth Rs. 99 crore.
With a market capitalization of Rs. 2,543.44 crores, the share of Solara Active Pharma Sciences Limited has reached an intraday high of Rs. 536.85 per equity share, rising nearly 5.53 percent from its previous day’s close price of Rs. 508.70. Since then, the stock has retreated and is currently trading at Rs. 528.20 per equity share.
On June 16, 2025, SPIRACCA VENTURES LLP and PRONOMZ VENTURES LLP exchanged their shares in the company through a block deal on the NSE. PRONOMZ VENTURES LLP, a promoter group, bought 20 lakh shares (4.16 percent stake) at an average price of Rs. 495, resulting in a transaction value of Rs. 99 crore on the NSE exchange. This purchase increased their holding from 26.74 lakh shares to 46.74 lakh shares, representing a 9.73 percent stake in the company.
On the same day, SPIRACCA VENTURES LLP sold 20 lakh shares (4.16 percent stake) at an average price of Rs. 495, totaling Rs. 99 crore, reducing their holding from 37.09 lakh shares to 17.09 lakh shares, which now represents a 3.56 percent stake in the company.
Solara Active Pharma Sciences Limited was established in 2018 and is an Indian pharmaceutical company specializing in the manufacturing, production, and sale of Active Pharmaceutical Ingredients (APIs) and providing contract research and manufacturing services (CRAMS).
For FY26, the company expects revenue to grow by around 10 percent year-on-year. EBITDA is projected to increase by 15–20 percent year-on-year, supported by better gross margins and improved operating efficiency. This reflects the company’s focus on strengthening profitability alongside steady revenue growth.
The company serves over 75 countries with a diverse product portfolio in therapeutic segments. It operates four API manufacturing plants that have approvals from global regulatory authorities. The company also has two dedicated R&D centers, where over 140 scientists work on developing and improving pharmaceutical products.
Coming into financial highlights, Solara Active Pharma Sciences Limited’s revenue has decreased from Rs. 299.43 crore in Q4 FY24 to Rs. 273.01 crore in Q4 FY25, which is a drop of 8.82 percent. The net loss of the company has reduced from Rs. 255.45 crore in Q4 FY24 to Rs. 2.10 crore in Q4 FY25.
In terms of return ratios, the company’s ROCE and ROE stand at 6.01 percent and 0.05 percent, respectively. Solara Active Pharma Sciences Limited has an earnings per share (EPS) of Rs. 0.15, and its debt-to-equity ratio is 0.73x.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
